Operator

Good afternoon, and welcome to the Santhera Pharmaceuticals Investor Presentation. [Operator Instructions] Before we begin, I'd like to submit the following poll.

I'd now like to hand you over to the management team. Dario, good morning, sir.

Dario Eklund
Chief Executive Officer

Thank you, Lilly. Good morning and for those in the U.S. who are joining us and good afternoon for those here in Europe, and welcome to this full year 2025 investor call. As usual, I'm today joined by Catherine Isted, who's our Chief Financial Officer; as well as Shabir Hasham, who is our Chief Medical Officer. They will both give their respective parts of the presentation and be here for the Q&A as well.

So can I have the next slide, please? Can we have the next slide after that? Here we go. Now, the disclaimer, please. Can we go back? So I just want to draw your attention to the greetings from our legal department here where you should, at your own leisure, read this if you're not familiar with the text. And with that, let's move into the actual presentation.

So 2025 was a really exciting year with expansion and global momentum continuing. This --these six points that you can see on this slide here really are the summary of our presentation. Today, we will have deeper dives on each of the six subjects. But I just want to highlight a few things here that, first of all, in Austria and Germany, we are continuing to make great progress. In Q1 of this year, we actually had 50% growth over last year, which means that in Germany, we're well over 40% penetrated in the